Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-1-8
pubmed:abstractText
An increased inflammatory response and deficient synthesis of neurotrophic factors (NTFs) may contribute to the etiology of depression. However, the interrelationship between inflammation and NTFs is unknown. Recently, ethyl-eicosapentaenoate (EPA) has been used to treat depression. The mechanism by which EPA benefits depression is also unclear. Using the olfactory bulbectomized (OB) rat model of depression, this study evaluated two pathways from bulbectomy to the induction of depression-like changes (the inflammation-hypothalamic-pituitary-adrenal axis-stress response pathway and inflammation-nerve growth factor-memory pathway) and the effect of EPA on these pathways. When compared with sham-operated rats fed a control diet, significantly increased locomotor and rearing activities in an "open field," impaired memory in the Morris water maze, increased expression of corticotrophin-releasing factor (CRF), and increased secretion of corticosterone were found in OB rats. mRNA expression of nerve growth factor (NGF) was significantly lower in the hippocampus, and phospholipase A2 (PLA2) was higher in the hypothalamus; this change was associated with increased interleukin-1beta (IL-1beta) and prostaglandin E2 (PGE2) in the serum and brain. EPA treatments normalized these behavioral impairments and reduced CRF expression and corticosterone secretion. EPA also reduced serum concentrations of IL-1beta and PGE2, but reversed NGF reduction. Similar to the effects of EPA, the anti-inflammatory drug celecoxib significantly reduced blood PGE2, IL-1beta, and corticosterone concentrations and increased NGF expression in OB rats. Furthermore, anti-NGF treatment blocked EPA effects on behavior. These results suggest that an interaction exists between inflammation and NGF in the depression model. EPA may improve depression via its anti-inflammation properties and the upregulation of NGF.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Corticosterone, http://linkedlifedata.com/resource/pubmed/chemical/Corticotropin-Releasing Hormone, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone, http://linkedlifedata.com/resource/pubmed/chemical/Eicosapentaenoic Acid, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1, http://linkedlifedata.com/resource/pubmed/chemical/Nerve Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/Phospholipases A2, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Pyrazoles, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/celecoxib, http://linkedlifedata.com/resource/pubmed/chemical/eicosapentaenoic acid ethyl ester
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1529-2401
pubmed:author
pubmed:issnType
Electronic
pubmed:day
7
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
14-22
pubmed:meshHeading
pubmed-meshheading:19129380-Analysis of Variance, pubmed-meshheading:19129380-Animals, pubmed-meshheading:19129380-Corticosterone, pubmed-meshheading:19129380-Corticotropin-Releasing Hormone, pubmed-meshheading:19129380-Cyclooxygenase Inhibitors, pubmed-meshheading:19129380-Depressive Disorder, pubmed-meshheading:19129380-Dinoprostone, pubmed-meshheading:19129380-Disease Models, Animal, pubmed-meshheading:19129380-Eicosapentaenoic Acid, pubmed-meshheading:19129380-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:19129380-Exploratory Behavior, pubmed-meshheading:19129380-Gene Expression Regulation, pubmed-meshheading:19129380-Hippocampus, pubmed-meshheading:19129380-Interleukin-1, pubmed-meshheading:19129380-Male, pubmed-meshheading:19129380-Maze Learning, pubmed-meshheading:19129380-Nerve Growth Factor, pubmed-meshheading:19129380-Olfactory Bulb, pubmed-meshheading:19129380-Phospholipases A2, pubmed-meshheading:19129380-Platelet Aggregation Inhibitors, pubmed-meshheading:19129380-Pyrazoles, pubmed-meshheading:19129380-RNA, Messenger, pubmed-meshheading:19129380-Rats, pubmed-meshheading:19129380-Rats, Sprague-Dawley, pubmed-meshheading:19129380-Sulfonamides
pubmed:year
2009
pubmed:articleTitle
Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment.
pubmed:affiliation
Department of Biomedical Sciences, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada C1A 4P3. cai.song@nrc.gc.ca
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't